期刊
CELL METABOLISM
卷 29, 期 3, 页码 719-+出版社
CELL PRESS
DOI: 10.1016/j.cmet.2018.10.008
关键词
-
资金
- Novo Nordisk Center for Basic Metabolic Research (Novo Nordisk Foundation, Denmark)
- Novo Nordisk [NNF15OC0016574]
- European Union's Seventh Framework Programme for Research, Technological Development, and Demonstration Activities [266408]
- European Research Council [695069]
- Lundbeck Foundation [R180-2014-2868]
- Danish Diabetes Academy - Novo Nordisk Foundation [OUH OL8201]
- Danish Diabetes Acadamy
- Department of Biomedical Sciences, University of Copenhagen
- Zealand Pharma A/S
- Lundbeck Foundation (Lundbeckfonden) [R264-2017-3492]
Studies on isolated pancreatic islets suggest that neuromedin U (NMU), a brain and gastrointestinal peptide, acts as a decretin hormone, inhibiting glucose-stimulated insulin secretion. We investigated whether this effect could be reproduced in vivo and in isolated perfused rat pancreas. Unlike the incretin hormone, glucagon-like peptide 1 (GLP-1), intravenous NMU administration had no effects on blood glucose and plasma insulin and glucagon in vivo. Moreover, NMU neither changed insulin, glucagon, or somatostatin secretion from isolated perfused rat pancreas, nor affected GLP-1-stimulated insulin and somatostatin secretion. For NMU to act as a decretin hormone, its secretion should increase following glucose ingestion; however, glucose did not affect NMU secretion from isolated perfused rat small intestine, which contained extractable NMU. Furthermore, the two NMU receptors were not detected in endocrine rat or human pancreas. We conclude that NMU does not act as a decretin hormone in rats.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据